# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Brian Abrahams reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and maintains $1282 ...
Cantor Fitzgerald analyst Olivia Brayer reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and maintains $101...
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Curre...
This approval expands the initial Health Canada Notice of Compliance for eosinophilic esophagitis in May 2023 for patients aged...
Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints.
Among the presentation highlights are several new post-hoc analyses of the pivotal PULSAR trial for EYLEA HD in wet age-related...
Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoin...
Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients ach...